{"id":204927,"date":"2026-08-14T15:41:03","date_gmt":"2026-08-14T10:11:03","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=204927"},"modified":"2026-08-14T15:41:04","modified_gmt":"2026-08-14T10:11:04","slug":"jeevan-scientific-q1-fy27-results-pat-88-lakh","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/","title":{"rendered":"Jeevan Scientific Q1 FY27 Results: Revenue More Than Doubles to Rs 18 Crore, Turns Profitable at Rs 88 Lakh"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Jeevan Scientific Q1 FY27: Revenue Rs 18 Cr (+107.72% YoY). PAT Rs 0.88 Cr vs loss Rs 3 Cr. Gross profit Rs 1 Cr vs Rs -3 Cr. CMP Rs 83.33 on Aug 13.<\/em><\/p>\n<div style=\"background: #F0F9FF; border-left: 4px solid #2E7D32; border-radius: 6px; padding: 14px 18px; margin: 18px 0;\">\n<p style=\"margin: 0; color: #1f4e79; font-size: 14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin: 8px 0 0;\">Jeevan Scientific delivered a transformational Q1 FY27 performance, with consolidated revenue more than doubling to Rs 18 crore from Rs 8 crore in Q1 FY26. PAT swung to a profit of Rs 0.88 crore from a loss of Rs 3 crore, and gross profit turned positive at Rs 1 crore from Rs -3 crore. Jeevan Scientific Q1 FY27 results represent a meaningful operational turnaround for the CRO and clinical research services company.<\/p>\n<\/div>\n<p>Jeevan Scientific Q1 FY27 results showed the Hyderabad-based contract research organisation (CRO) delivering a 107.72% revenue surge to Rs 18 crore from Rs 8 crore in Q1 FY26 on a consolidated basis. The doubling of revenue reflects either significant new clinical trial contracts, expansion of the company&#8217;s bioequivalence and bioanalytical services, or new pharmaceutical customer additions.<\/p>\n<p>The Jeevan Scientific Q1 FY27 results showed gross profit swinging dramatically from Rs -3 crore to Rs 1 crore alongside the revenue doubling. Net profit turned positive at Rs 0.88 crore from a loss of Rs 3 crore in Q1 FY26. This turnaround reflects the operating leverage of the CRO business model, where once revenue reaches sufficient scale to cover fixed laboratory and employee costs, the incremental revenue flows rapidly to profitability.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=jeevan-scientific-q1fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#Jeevan_Scient_Q1_FY27_Financial_Highlights\" title=\"Jeevan Scient Q1 FY27 Financial Highlights\">Jeevan Scient Q1 FY27 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#Jeevan_Scient_Q1_FY27_Performance_Analysis\" title=\"Jeevan Scient Q1 FY27 Performance Analysis\">Jeevan Scient Q1 FY27 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#Key_Business_Factors_in_Q1_FY27\" title=\"Key Business Factors in Q1 FY27\">Key Business Factors in Q1 FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#Revenue_Doubling_Through_CRO_Growth\" title=\"Revenue Doubling Through CRO Growth\">Revenue Doubling Through CRO Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#Operating_Leverage_at_CRO_Scale\" title=\"Operating Leverage at CRO Scale\">Operating Leverage at CRO Scale<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#Pharmaceutical_R_D_Outsourcing\" title=\"Pharmaceutical R&amp;D Outsourcing\">Pharmaceutical R&amp;D Outsourcing<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#Dividend_Details\" title=\"Dividend Details\">Dividend Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#FY27_Outlook\" title=\"FY27 Outlook\">FY27 Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#Jeevan_Scient_Stock_Performance\" title=\"Jeevan Scient Stock Performance\">Jeevan Scient Stock Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#Key_Risks\" title=\"Key Risks\">Key Risks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#Revenue_Lumpiness_in_CRO_Business\" title=\"Revenue Lumpiness in CRO Business\">Revenue Lumpiness in CRO Business<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#Regulatory_and_Compliance_Risk\" title=\"Regulatory and Compliance Risk\">Regulatory and Compliance Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#Competition_from_Larger_Indian_CROs\" title=\"Competition from Larger Indian CROs\">Competition from Larger Indian CROs<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#Frequently_Asked_Questions_on_Jeevan_Scient_Q1_FY27_Results\" title=\"Frequently Asked Questions on Jeevan Scient Q1 FY27 Results\">Frequently Asked Questions on Jeevan Scient Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#When_were_Jeevan_Scientific_Q1_FY27_results_announced\" title=\"When were Jeevan Scientific Q1 FY27 results announced?\">When were Jeevan Scientific Q1 FY27 results announced?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#What_was_Jeevan_Scientifics_revenue_in_Q1_FY27\" title=\"What was Jeevan Scientific&#8217;s revenue in Q1 FY27?\">What was Jeevan Scientific&#8217;s revenue in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#Did_Jeevan_Scientific_turn_profitable_in_Q1_FY27\" title=\"Did Jeevan Scientific turn profitable in Q1 FY27?\">Did Jeevan Scientific turn profitable in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#What_drove_Jeevan_Scientifics_revenue_to_double_in_Q1_FY27\" title=\"What drove Jeevan Scientific&#8217;s revenue to double in Q1 FY27?\">What drove Jeevan Scientific&#8217;s revenue to double in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#Did_Jeevan_Scientific_declare_a_dividend_after_Q1_FY27_results\" title=\"Did Jeevan Scientific declare a dividend after Q1 FY27 results?\">Did Jeevan Scientific declare a dividend after Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#What_is_the_outlook_for_Jeevan_Scientific_after_Q1_FY27_results\" title=\"What is the outlook for Jeevan Scientific after Q1 FY27 results?\">What is the outlook for Jeevan Scientific after Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/jeevan-scientific-q1-fy27-results-pat-88-lakh\/#Is_Jeevan_Scientific_a_good_investment_after_Q1_FY27_results\" title=\"Is Jeevan Scientific a good investment after Q1 FY27 results?\">Is Jeevan Scientific a good investment after Q1 FY27 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Jeevan_Scient_Q1_FY27_Financial_Highlights\"><\/span><strong>Jeevan Scient Q1 FY27 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse: collapse; width: 100%; margin: 16px 0;\" border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<thead style=\"background: #1F4E79; color: #ffffff;\">\n<tr>\n<th>Metric<\/th>\n<th>Q1 FY27 (Rs Crore)<\/th>\n<th>Q1 FY26 (Rs Crore)<\/th>\n<th>YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue<\/td>\n<td>18.00<\/td>\n<td>8.00<\/td>\n<td>+107.72%<\/td>\n<\/tr>\n<tr>\n<td>Gross Profit<\/td>\n<td>1.00<\/td>\n<td>-3.00<\/td>\n<td>+135.46%<\/td>\n<\/tr>\n<tr>\n<td>Net Profit \/ PAT<\/td>\n<td>0.88<\/td>\n<td>-3.00<\/td>\n<td>+127.23%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Jeevan_Scient_Q1_FY27_Performance_Analysis\"><\/span><strong>Jeevan Scient Q1 FY27 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Use the Univest Screener to track Jeevan Scient live financials and Q1 FY27 results<\/strong><\/a><\/p>\n<p>Jeevan Scientific Q1 FY27 results represent a significant inflection point for the company. Revenue doubling from Rs 8 crore to Rs 18 crore has crossed the operating breakeven threshold, turning the business from deeply loss-making to marginally profitable. For CRO businesses with high fixed laboratory infrastructure and skilled scientist costs, revenue scaling to cover these fixed costs is the critical milestone.<\/p>\n<p>The gross profit swing in Jeevan Scientific Q1 FY27 results from Rs -3 crore to Rs 1 crore on Rs 10 crore of additional revenue implies a gross contribution rate of approximately 40% on the incremental revenue. This is consistent with CRO businesses where additional clinical studies can be accommodated within the existing laboratory capacity without proportionate cost increases.<\/p>\n<p>The PAT of Rs 0.88 crore in Jeevan Scientific Q1 FY27 results, swinging from a loss of Rs 3 crore, is modest in absolute terms but represents a Rs 3.88 crore improvement \u2014 highly meaningful for a company of this scale. Sustaining and growing this profit will require continued revenue scaling through new clinical trial mandates.<\/p>\n<p>Jeevan Scientific Q1 FY27 results suggest the company has successfully expanded its CRO service portfolio and customer base to achieve revenue scale. The pharmaceutical sector&#8217;s growing R&amp;D spending, particularly in generics for regulated markets, provides a structural demand tailwind for quality Indian CROs.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Business_Factors_in_Q1_FY27\"><\/span><strong>Key Business Factors in Q1 FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_Doubling_Through_CRO_Growth\"><\/span><strong>Revenue Doubling Through CRO Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 108% revenue jump in Jeevan Scientific Q1 FY27 results from Rs 8 crore to Rs 18 crore reflects significant new clinical trial and research contract wins. Indian CROs are benefiting from global pharmaceutical companies&#8217; increasing R&amp;D outsourcing to cost-competitive Indian facilities.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Operating_Leverage_at_CRO_Scale\"><\/span><strong>Operating Leverage at CRO Scale<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The gross profit swing from Rs -3 crore to Rs 1 crore on Rs 10 crore additional revenue in Jeevan Scientific Q1 FY27 results demonstrates the operating leverage inherent in laboratory-based research services. Once the capacity and scientist base is in place, incremental studies contribute significantly to profitability.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Pharmaceutical_R_D_Outsourcing\"><\/span><strong>Pharmaceutical R&amp;D Outsourcing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s CRO sector benefits from the global pharmaceutical industry&#8217;s increasing R&amp;D outsourcing to India, driven by cost advantages and the availability of qualified clinical research professionals. Jeevan Scientific Q1 FY27 results reflect the company capturing this structural growth in the Indian CRO market.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Details\"><\/span><strong>Dividend Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Jeevan Scientific has not declared a dividend for Q1 FY27. The company is in a growth and scaling phase in the CRO business, and earnings are expected to be reinvested in laboratory capacity and regulatory capabilities rather than distributed as dividends.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"FY27_Outlook\"><\/span><strong>FY27 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The FY27 outlook for Jeevan Scientific is positive following the Q1 FY27 results turnaround. If the revenue momentum is sustained and the company continues to win new clinical trial mandates, operating leverage should continue to improve PAT through Q2 and Q3 FY27.<\/p>\n<p>Key risks include the competitive landscape in Indian CROs, the lumpy nature of clinical trial project revenue, and any regulatory challenges from global health authorities that could delay approvals or reduce the attractiveness of Indian CRO studies for multinational pharmaceutical companies.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Jeevan_Scient_Stock_Performance\"><\/span><strong>Jeevan Scient Stock Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Jeevan Scient share price live and stay updated on quarterly results.<\/em><\/p>\n<p>Jeevan Scientific shares traded at Rs 83.33 on August 13, 2026, up 6.13% on the day, reflecting strong market enthusiasm for the revenue doubling and PAT turnaround in Q1 FY27 results. The stock&#8217;s continued performance will depend on sustaining the revenue momentum through subsequent quarters.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks\"><\/span><strong>Key Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_Lumpiness_in_CRO_Business\"><\/span><strong>Revenue Lumpiness in CRO Business<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Clinical trial revenue in CRO businesses is project-based and can be lumpy. If Q1 FY27 results benefited from a particularly strong project delivery quarter, Q2 FY27 may see some moderation if new projects are not yet in the execution phase.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Regulatory_and_Compliance_Risk\"><\/span><strong>Regulatory and Compliance Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>CRO businesses operate under strict regulatory oversight from CDSCO, FDA, and other global health authorities. Any compliance findings or warning letters could disrupt operations and reduce new mandate wins, impacting revenue from Q1 FY27 results levels.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Competition_from_Larger_Indian_CROs\"><\/span><strong>Competition from Larger Indian CROs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Indian CRO market includes well-established players like Syngene, Jubilant Biosys, and Divi&#8217;s Laboratories. Competing for complex global pharmaceutical mandates requires continuous investment in laboratory infrastructure, which could add to costs even as revenues scale.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Jeevan Scientific Q1 FY27 results represent a meaningful operational turnaround, with revenue more than doubling to Rs 18 crore and PAT swinging to Rs 0.88 crore from a loss of Rs 3 crore. The results validate the company&#8217;s scaling strategy in the growing Indian CRO sector.<\/p>\n<p>Sustaining the revenue momentum and converting it to improving profitability will be the key test in Q2 and Q3 FY27. Investors should monitor new contract wins and regulatory compliance status alongside the Jeevan Scientific Q1 FY27 results trajectory. Consult a SEBI-registered advisor before investing.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Jeevan_Scient_Q1_FY27_Results\"><\/span><strong>Frequently Asked Questions on Jeevan Scient Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_were_Jeevan_Scientific_Q1_FY27_results_announced\"><\/span><strong>When were Jeevan Scientific Q1 FY27 results announced?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Jeevan Scientific Q1 FY27 results were announced on August 13, 2026, covering the April to June 2026 quarter on a consolidated basis.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Jeevan_Scientifics_revenue_in_Q1_FY27\"><\/span><strong>What was Jeevan Scientific&#8217;s revenue in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Jeevan Scientific reported consolidated revenue of Rs 18 crore in Q1 FY27, up 107.72% from Rs 8 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Jeevan_Scientific_turn_profitable_in_Q1_FY27\"><\/span><strong>Did Jeevan Scientific turn profitable in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Yes, Jeevan Scientific Q1 FY27 results show the company turning profitable with a net profit of Rs 0.88 crore, swinging from a loss of Rs 3 crore in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_drove_Jeevan_Scientifics_revenue_to_double_in_Q1_FY27\"><\/span><strong>What drove Jeevan Scientific&#8217;s revenue to double in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Jeevan Scientific Q1 FY27 results reflect significant new CRO contract wins and scaling of clinical trial services. The global pharmaceutical industry&#8217;s increasing R&amp;D outsourcing to India, combined with the company&#8217;s expanded capabilities, drove the revenue doubling.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Jeevan_Scientific_declare_a_dividend_after_Q1_FY27_results\"><\/span><strong>Did Jeevan Scientific declare a dividend after Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Jeevan Scientific has not declared a dividend for Q1 FY27. The company is reinvesting earnings in CRO capacity and business development.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_outlook_for_Jeevan_Scientific_after_Q1_FY27_results\"><\/span><strong>What is the outlook for Jeevan Scientific after Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The FY27 outlook is positive, supported by the structural growth in Indian CRO services. Sustaining the revenue momentum and managing project-level lumpiness will be key.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Jeevan_Scientific_a_good_investment_after_Q1_FY27_results\"><\/span><strong>Is Jeevan Scientific a good investment after Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Jeevan Scientific Q1 FY27 results show a meaningful turnaround with revenue doubling and PAT turning positive. Investors should assess new contract pipeline and regulatory standing before investing. Consult a SEBI-registered advisor.<\/p>\n<div class=\"faq-schema\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jeevan Scientific Q1 FY27 results showed consolidated revenue doubling to Rs 18 crore and PAT swinging to Rs 88 lakh from a loss of Rs 3 crore in Q1 FY26 as gross profit also turned positive.<\/p>\n","protected":false},"author":36,"featured_media":204926,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[3802],"class_list":["post-204927","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["204926"],"_edit_lock":["1786702268:36"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["24"],"rank_math_seo_score":["77"],"rank_math_title":["Jeevan Scientific Q1 FY27 Results: Revenue Doubles, PAT Rs 88 Lakh"],"rank_math_description":["Jeevan Scientific Q1 FY27 results: Revenue more than doubled to Rs 18 crore from Rs 8 crore in Q1 FY26 while PAT swung to Rs 88 lakh from a loss. Detailed analysis of the CRO company."],"rank_math_focus_keyword":["Jeevan Scientific Q1"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["36"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["37570"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/jeevan-scientific-q1-fy27-results-pat-88-lakh.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/204927","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=204927"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/204927\/revisions"}],"predecessor-version":[{"id":204968,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/204927\/revisions\/204968"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/204926"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=204927"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=204927"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=204927"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}